Euromedis Groupe publishes its annual results for 2023

The Board of Directors of Euromedis Groupe finalized the accounts for the 2023 financial year on April 26, 2024. The year was marked by the sale of Paramat and the merger-absorption of Laboratoires Euromedis by Euromedis Groupe. These changes resulted in the removal of the obligation to prepare consolidated accounts, thus simplifying financial presentation.

Revenue reached 34.0 million euros, down 37%, with a gross margin of 9.0 million euros, down 26%. Nevertheless, profit before tax amounted to 21.0 million euros thanks to exceptional operations linked to recent restructuring. The group's net profit also increased considerably, reaching 13.1 million euros.

Business in 2023 benefited from reduced ocean freight costs and moderation in price fluctuations. However, instability in the Middle East and Ukraine has affected the cost structure and currency management.

For 2024, the company anticipates activity remaining at a stable level, despite persistent geopolitical and economic uncertainties. The impact of these factors could affect profitability projections for the current year.